

1 **A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses**  
2 **independently of the interval between the first two doses**

3 Alexandra Tauzin<sup>1,2</sup>, Shang Yu Gong<sup>1,3</sup>, Mark M. Painter<sup>4,5,6</sup>, Rishi R. Goel<sup>4,5</sup>, Debashree  
4 Chatterjee<sup>1</sup>, Guillaume Beaudoin-Bussi eres<sup>1,2</sup>, Lorie Marchitto<sup>1,2</sup>, Marianne Boutin<sup>1,2</sup>, Annemarie  
5 Laumaea<sup>1,2</sup>, James Okeny<sup>7</sup>, Gabrielle Gendron-Lepage<sup>1</sup>, Catherine Bourassa<sup>1</sup>, Halima  
6 Medjahed<sup>1</sup>, Guillaume Goyette<sup>1</sup>, Justine C. Williams<sup>5</sup>, Yuxia Bo<sup>7</sup>, Laurie Gokool<sup>1</sup>, Chantal  
7 Morrisseau<sup>1</sup>, Pascale Arlotto<sup>1</sup>, Ren e Bazin<sup>8</sup>, Judith Fafard<sup>9</sup>, C ecile Tremblay<sup>1,2</sup>, Daniel E.  
8 Kaufmann<sup>1,10</sup>, Gaston De Serres<sup>11</sup>, Marceline C ot e<sup>7</sup>, Ralf Duerr<sup>12</sup>, Val erie Martel-Laferr iere<sup>1,2</sup>,  
9 Allison R. Greenplate<sup>4,5</sup>, E. John Wherry<sup>4,5,6</sup> and Andr es Finzi<sup>1,2,3,13,\*</sup>

10 <sup>1</sup>Centre de Recherche du CHUM, Montreal, QC, H2X 0A9 Canada

11 <sup>2</sup>D epartement de Microbiologie, Infectiologie et Immunologie, Universit  de Montr al, Montreal, QC, H2X  
12 0A9, Canada

13 <sup>3</sup>Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada

14 <sup>4</sup>Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA  
15 19104, USA

16 <sup>5</sup>Immune Health<sup> </sup>, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

17 <sup>6</sup>Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania  
18 Perelman School of Medicine, Philadelphia, PA 19104, USA

19 <sup>7</sup>Department of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and  
20 Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada

21 <sup>8</sup>H ema-Qu ebec, Affaires M dicales et Innovation, Quebec, QC G1V 5C3, Canada

22 <sup>9</sup>Laboratoire de Sant  Publique du Qu ebec, Institut national de sant  publique du Qu ebec, Sainte-Anne-  
23 de-Bellevue, QC H9X 3R5, Canada

24 <sup>10</sup>D epartement de M decine, Universit  de Montr al, Montreal, QC, H3T 1J4, Canada

25 <sup>11</sup>Institut National de Sant  Publique du Qu ebec, Quebec, QC H2P 1E2, Canada

26 <sup>12</sup>Department of Microbiology, New York University School of Medicine, New York, NY, 10016, USA

27

28

29 <sup>13</sup>Lead contact

30 \*Correspondence: [andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca) (A.F.)

31

32

### 33 **SUMMARY**

34 Due to the recrudescence of SARS-CoV-2 infections worldwide, mainly caused by Omicron BA.1  
35 and BA.2 variants of concern, several jurisdictions are administering a mRNA vaccine boost.  
36 Here, we analyzed humoral responses induced after the second and third doses of mRNA vaccine  
37 in naïve and previously-infected donors who received their second dose with an extended 16-  
38 week interval. We observed that the extended interval elicited robust humoral responses against  
39 VOCs, but this response was significantly diminished 4 months after the second dose.  
40 Administering a boost to these individuals brought back the humoral responses to the same levels  
41 obtained after the extended second dose. Interestingly, we observed that administering a boost  
42 to individuals that initially received a short 3-4 weeks regimen elicited humoral responses similar  
43 to those elicited in the long interval regimen. Nevertheless, humoral responses elicited by the  
44 boost in naïve individuals did not reach those present in previously-infected vaccinated  
45 individuals.

46 **Keywords:** Coronavirus, COVID-19, SARS-CoV-2, Spike glycoproteins, Long interval, Third  
47 mRNA vaccine dose, Humoral responses, Variants of concern

## 48 INTRODUCTION

49 Two years after the coronavirus disease 2019 (COVID-19) was declared pandemic by the  
50 WHO, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to circulate  
51 worldwide and has evolved in several variants. The variants of concern (VOCs), defined as  
52 variants with increased transmissibility, virulence and/or against which vaccines and monoclonal  
53 antibody treatments are less effective (WHO, 2022a), are now the main source of concern about  
54 the evolving pandemic. Currently, the Delta and Omicron variants are the main circulating VOCs.  
55 The Delta (B.1.617.2) variant was declared as a VOC on May 2021 and the Omicron (B.1.1.529)  
56 variant in November 2021 (Choi and Smith, 2021; WHO, 2022a). Delta became the dominant  
57 strain in the summer/autumn of 2021. Omicron is divided into several sub-lineages: BA.1 (the  
58 main, named Omicron hereafter), BA.1.1, BA.2 and BA.3 (Kumar et al., 2022; Viana et al., 2022).  
59 Due to its relatively high number of mutations, notably in the Spike (S) glycoprotein, Omicron is  
60 more resistant to humoral responses elicited by vaccination or natural infection. This phenotype,  
61 in combination with a higher transmissibility rate compared to Delta, likely explains why it became  
62 the dominant strain worldwide by January 2022 (Chen et al., 2022; Dhar et al., 2021).

63 Vaccination campaigns began over a year ago and, in several parts of the world, public  
64 health authorities are administering a third dose of vaccine (boost). Vaccine scarcity at the  
65 beginning of the vaccination campaign led some public health authorities to increase the interval  
66 between the first two doses, notably in the province of Quebec, Canada, where this interval was  
67 delayed to 16 weeks instead of 3-4 weeks. Several studies have now shown that this strategy  
68 leads to improved humoral, T and B cell responses after the second dose in comparison to the  
69 short vaccine regimen, in particular against VOCs including Delta and Omicron variants  
70 (Chatterjee et al., 2021; Nayrac et al., 2021; Payne et al., 2021; Tauzin et al., 2022a).

71 A vaccine boost is now recommended in several jurisdictions worldwide in response to the  
72 Omicron wave (Ferdinands, 2022). Recent studies have shown that this boost, following the 3-4

73 weeks dose interval regimen, strongly improves humoral responses against VOCs, for which poor  
74 responses were observed after the second dose (Doria-Rose et al., 2021; Gruell et al., 2022;  
75 Nemet et al., 2022; Schmidt et al., 2022). Here, we analyzed humoral responses elicited after the  
76 second and the third dose of mRNA vaccine in a cohort of SARS-CoV-2 naïve and previously  
77 infected donors who received their first two doses of Pfizer BioNTech mRNA vaccine with a 16-  
78 weeks interval and compared to individuals receiving a short interval.

79

## 80 RESULTS

81 We analyzed humoral responses induced after the second and the third doses of  
82 BNT162b2 mRNA vaccine in a cohort of donors who received their first two doses with an  
83 extended interval of 16 weeks (median [range]: 111 days [76–134 days]). These donors received  
84 their third dose around seven months after the second dose (median [range]: 219 days [167-235  
85 days]). The cohort included 20 SARS-CoV-2 naïve and 11 previously infected (PI) individuals who  
86 tested SARS-CoV-2 positive by nasopharyngeal swab PCR around 10 months before their first  
87 dose (median [range]: 300 days [247-321 days]). Blood samples were analyzed three weeks (V3,  
88 median [range]: 21 days [13–42 days]) and four months (V4, median [range]: 112 days [90–156  
89 days]) after the second dose and four weeks (V5, median [range]: 27 days [19–38 days]) after the  
90 third dose of mRNA vaccine. Basic demographic characteristics of the cohorts and detailed  
91 vaccination time points are summarized in Table 1 and Figure 1A.

92

### 93 **Anti-RBD IgG levels of vaccine-elicited antibodies**

94 We first measured the level of anti-receptor-binding domain (RBD) IgG induced after the  
95 second and the third doses of mRNA vaccine by ELISA assay (Anand et al., 2021; Beaudoin-  
96 Bussièrès et al., 2020; Prévost et al., 2020; Tauzin et al., 2021). Three weeks after the second  
97 dose of mRNA vaccine (V3), both naïve and PI individuals presented high levels of anti-RBD IgG  
98 (Figure 1B). Four months after the second dose (V4), the level of antibodies (Abs) decreased for  
99 both groups reaching significantly lower levels for naïve individuals, in agreement with previous  
100 observations (Tauzin et al., 2022a). The third dose (V5) led to an increase of anti-RBD IgG level,  
101 similar in both groups, that reached the same levels than after the second dose (V3) (Figure 1B).

102

103

104

## 105 **Recognition of SARS-CoV-2 Spike variants by plasma from vaccinated individuals**

106 We evaluated the ability of plasma IgG to recognize SARS-CoV-2 full-length S variants  
107 after the second and the third dose of vaccine (Figure 1 C-G). After the second dose, plasma from  
108 naïve donors recognized the D614G S less efficiently than plasma from PI individuals (Figure 1C).  
109 Four months after the second dose (V4), we observed a decreased recognition for both groups,  
110 but more pronounced in the naïve group. The third dose (V5) increased D614G S recognition by  
111 the naïve group, reaching levels similar to those achieved after the second dose (V3) (Figure 1C).  
112 However, even after the boost, the level of recognition in naïve donors did not reach the same  
113 level as in the PI group.

114 The original Wuhan strain was used to develop mRNA SARS-CoV-2 vaccines. Numerous  
115 mutations, particularly in the S glycoprotein, reduced the ability of vaccine-induced Abs to  
116 recognize currently circulating strains. We tested the S recognition of several VOCs in circulation  
117 after mRNA vaccination (Figure 1D-G, S2C-E). For all the VOCs S tested, a similar pattern of  
118 response than for D614G S was observed. Except for Omicron and BA.1.1 S at V5, plasma from  
119 PI donors more efficiently recognized S variants than naïve donors at all time points. Again,  
120 booster-elicited antibodies able to recognize the different S glycoproteins reached levels similar  
121 as those obtained after the second dose (Figure 1D-G). Comparable responses were observed  
122 when we measured the capacity of plasma to recognize the S2 subunit (Figure S1A).

123 We also evaluated whether the booster impacted the capacity of plasma to recognize the  
124 S glycoprotein of the endemic HKU1 human *Betacoronaviruses* (Figure S1B). We did not observe  
125 major changes in recognition after the second and third doses. However, for all time points plasma  
126 from PI donors always recognized better the HCoV-HKU1 S than the naïve group. This suggests  
127 that natural infection elicits more cross-reactive antibodies.

128

129

130

## 131 **Functional activities of vaccine-elicited antibodies**

132 We evaluated functional activities of vaccine-elicited Abs after the second and third doses  
133 (Figure 2). We measured Fc-effector functions using a well-described antibody-dependent cellular  
134 cytotoxicity (ADCC) assay (Anand et al., 2021; Beaudoin-Bussi eres et al., 2020, 2021; Ullah et  
135 al., 2021). Plasma from PI individuals presented significantly higher ADCC activity after the  
136 second dose (V3 and V4) with na ive individuals reaching similar levels after the third dose (V5)  
137 (Figure 2A). We noted that while ADCC remained relatively stable over time for PI individuals, it  
138 significantly decreased 4 months after the second dose for na ive individuals (V4). A similar pattern  
139 of responses was observed for the neutralizing activity against pseudoviruses carrying the D614G  
140 S (Figure 2B). At the three time points, the neutralizing activity was better in the PI group  
141 compared to na ive group. The level of neutralizing Abs remained stable in PI individuals whereas  
142 it significantly decreased in na ive donors at V4 but was significantly increased by the boost.

143 When looking at the neutralizing activity against VOCs, we observed that plasma from PI  
144 group more efficiently neutralized all pseudoviruses than the na ive group after the second dose  
145 (Figure 2C-D, S2). Interestingly, this difference disappeared after the boost (V5) (Figure S2).

146

## 147 **Integrated analysis of vaccine responses elicited by the second and third doses**

148 We evaluated the network of pairwise correlations among all studied immune variables on  
149 11 randomly selected na ive donors and the 11 PI individuals. For SARS-CoV-2 na ive individuals  
150 (Figure 3A), we observed a dense network of positive correlations after the second dose (V3)  
151 involving all immune variables tested, except for HCoV-HKU1 S binding. Four months after the  
152 second dose, this network became less dense, and the third dose did not substantially alter the  
153 network of correlations except for improved correlations of neutralization responses against  
154 Omicron and BA.1.1 with other anti-SARS-CoV-2 immune responses. Interestingly, in PI  
155 individuals, the integrated network was less dense after the second dose compared to na ive  
156 donors (Figure 3B), suggesting a less focused immune response possibly due to the

157 heterogenous immune stimulations by natural infection and vaccination. Whereas the network  
158 became slightly denser among the S binding responses four months after the second dose, it  
159 remained sparsely connected overall without major changes after the third dose of the mRNA  
160 vaccine.

161  
162 **Evolution of anti-RBD avidity induced after a short or a long interval between mRNA**  
163 **vaccine doses.**

164 We and others previously described that an extended interval between the first two doses  
165 of mRNA vaccine led to better humoral and cellular responses than the 3-4 weeks standard  
166 regimen, especially against VOCs (Nayrac et al., 2021; Payne et al., 2021; Tausin et al., 2022a).  
167 However, whether the humoral advantages observed with the long interval persist after the boost  
168 remains unclear. To address this important question, we measured longitudinally the level of anti-  
169 RBD IgG in cohorts of naïve and PI individuals that received their first two doses with the standard  
170 (short interval, SI) or the extended regimen (long interval, LI). Basic demographic characteristics  
171 of the cohorts and detailed vaccination time points are summarized in Table 2 and Figure 4A.  
172 Collection time points did not perfectly match between the two cohorts rendering perilous a side-  
173 by-side comparison using assays that only measure antibody quantities rather than their quality.  
174 We therefore decided to measure the avidity for the RBD of the induced IgG by a previously  
175 described assay (Björkman et al., 1999; Fialová et al., 2017; Tausin et al., 2022b). This assay  
176 consists of parallel ELISAs with washing buffer having or not a chaotropic agent (8M urea). The  
177 RBD-avidity index therefore becomes a surrogate of antibody maturation since only Abs with the  
178 highest avidity remain attached to the RBD after 8M urea washing (Figure S3).

179 Anti-RBD antibodies reached their peak level faster with the SI compared to the LI in naïve  
180 individuals (Figure 4B). While antibody levels rapidly decreased after the second dose in the SI  
181 regimen, the decay in the LI group was slower. In both groups, a booster elicited the highest levels



182 of antibodies. Consistent with the proposed use of the RBD-avidity index as a surrogate for  
183 antibody maturation, the kinetics differed from those of the regular ELISA that only measure total  
184 levels of anti-RBD Abs. For example, 12 weeks after the first dose in the LI regimen, there was a  
185 significant decline in anti-RBD IgG levels but the affinity of anti-RBD Abs likely improved as shown  
186 by an increase in their avidity (Figure 4B and D), consistent with recent results (Tauzin et al.,  
187 2022b). We previously reported that several humoral responses, including RBD-avidity was lower  
188 in individuals receiving a SI (Tauzin et al., CHM 2022). However, whether this difference remained  
189 after the boost was unknown. Here we report that the boost brought the RBD-avidity index to the  
190 same level, independent of the vaccine regimen, suggesting that the boost is required to further  
191 improve antibody responses in naïve individuals that received the SI regimen (Figure 4D).

192 For the PI groups, the SI and LI led rapidly to high levels of IgG (Figure 4C). These levels  
193 slightly decreased over time, however they remained more stable in the LI group, likely due to the  
194 delayed dose. After the boost, we observed similar levels of IgG in both groups. Regarding the  
195 avidity, the SI rapidly led to IgG with strong avidity which remained stable over time with only a  
196 minor effect induced by the boost (Figure 4E). For the LI group, the first dose increased the avidity,  
197 but to a lower extent than in the SI group. The second dose boosted the avidity to the same level  
198 than in the SI group. As observed in the SI group, the boost did not improve the avidity, indicating  
199 that individuals that developed hybrid immunity due to natural infection already had a higher  
200 antibody avidity than naïve vaccinated individuals.

201

## 202 DISCUSSION

203           Currently, a large part of the world population has received two or three doses of SARS-  
204 CoV-2 mRNA vaccines (WHO, 2022b). These vaccines were based on the ancestral Wuhan  
205 strain. One of the major challenges of the pandemic is the frequent emergence of variants that  
206 are more resistant to vaccine-elicited humoral responses, thus fueling new waves. In this study,  
207 we found that individuals who received their first two doses of mRNA vaccine with a 16-week  
208 extended interval had strong humoral responses against VOCs induced after the second dose.  
209 These responses significantly decreased 4 months later but came back to peak levels after the  
210 boost.

211           Many studies have shown that an extended interval between doses elicits humoral  
212 responses that outperform those elicited by a short interval in SARS-CoV-2 naïve individuals.  
213 Accordingly, we observed a network of correlation less dense after the second dose in individuals  
214 vaccinated with a SI in comparison to a LI (Figure 3A and S4). However, the third dose of mRNA  
215 vaccine, administered several months after the second dose in the SI regimen, strongly improved  
216 the humoral responses against VOCs (Figure S5), and the network of correlations became  
217 denser, as observed after the LI regimen (Figure 3A and S4), emphasising the importance of  
218 administering the boost.

219           Antibody maturation is a complex process that takes place in the germinal center (Young  
220 and Brink, 2021). This process is important for vaccine efficacy since it allows the immune system  
221 to generate antibodies with greater potency for viral neutralization and Fc-effector functions. We  
222 recently developed a high-throughput assay that could be used as a surrogate for antibody  
223 maturation (Tauzin et al., 2022b). Using this assay, we observed that the avidity of anti-RBD Abs  
224 was significantly higher in the LI after the second dose compared to the SI, suggesting that  
225 increasing the time between exposure to the antigen led to a better maturation of the B cells and  
226 so to Abs with higher avidity (Tauzin et al., 2022a). Here we report that a boost allows the SI

227 group to elicit Abs with the same avidity as in the LI group. Since the RBD is highly immunogenic,  
228 it is possible that humoral responses against this domain compromise responses against less  
229 immunogenic domains of the Spike. Thus, in future studies it would be interesting to measure  
230 the evolution of the avidity against other Spike domains.

231 Vaccinated PI individuals presented a better avidity than naïve individuals at all time  
232 points. These results are consistent with previous observations indicating that hybrid immunity  
233 led to broad and stronger humoral responses, but the mechanisms remain unclear (Andreano et  
234 al., 2021; Crotty, 2021; Goel et al., 2021). In correlation networks after the second and third doses  
235 of mRNA vaccine, we observed strikingly different profiles of correlations in naïve compared to PI  
236 donors suggesting that infection primes the immune system in a different way than vaccination  
237 does. Whether this is linked to the immune stimulation with all components of the entire virus or  
238 the transmission mode of SARS-CoV-2 which infects host by the mucosa, therefore activating  
239 resident immune cells, remains poorly understood.

240 While vaccination confers good protection against severe COVID-19, it is less efficient  
241 against viral transmission. Thus, breakthrough infection in vaccinated individuals appears  
242 frequently. It was recently shown that breakthrough infection in vaccinated individuals induced  
243 strong neutralizing Abs efficient against VOCs, including Omicron (Miyamoto et al., 2022).  
244 Interestingly, a LI between vaccination and breakthrough infection also induced better humoral  
245 responses against VOCs than a SI, as observed for vaccination. It is possible that breakthrough  
246 infection in fully vaccinated individuals led to hybrid immunity with humoral responses as strong  
247 as those observed in infected-then-vaccinated individuals. Moreover, it will be interesting to see  
248 the impact of breakthrough infection on the avidity of the Abs.

249 The third dose of SARS-CoV-2 mRNA vaccine led to high levels of humoral responses  
250 against VOCs, irrespective of the interval between the two first doses. We do not yet know about  
251 the durability of this immunity but epidemiological studies have shown a decline in vaccine

252 effectiveness against Omicron within a few months of the third dose (Andrews et al., 2022). We  
253 observed a rapid decrease of Ab levels after the first and second dose with both intervals and to  
254 a greater extent in SARS-CoV-2 naïve donors. However, it is possible that while humoral  
255 responses rapidly decreased after vaccination, cellular responses remain stable. Monitoring the  
256 evolution of humoral and cellular responses after the third dose of vaccine, and in particular in the  
257 numerous individuals who had Omicron or BA.2 breakthrough infection after their third dose, will  
258 be necessary to determine the need for additional boosts, the best interval time between dose  
259 injections, and the populations to be targeted (general population or only population at risk).

260

261

## 262 **ACKNOWLEDGMENTS**

263           The authors are grateful to the donors who participated in this study. The authors thank  
264 the CRCHUM BSL3 and Flow Cytometry Platforms for technical assistance. We thank Dr. Stefan  
265 Pöhlmann (Georg-August University, Germany) for the plasmid coding for SARS-CoV-2 S  
266 glycoproteins and Dr. M. Gordon Joyce (U.S. MHRP) for the monoclonal antibody CR3022. This  
267 work was supported by le Ministère de l'Économie et de l'Innovation du Québec, Programme de  
268 soutien aux organismes de recherche et d'innovation to A.F. and by the Fondation du CHUM.  
269 This work was also supported by a CIHR foundation grant #352417, by a CIHR operating  
270 Pandemic and Health Emergencies Research grant #177958, a CIHR stream 1 and 2 for SARS-  
271 CoV-2 Variant Research to A.F., and by an Exceptional Fund COVID-19 from the Canada  
272 Foundation for Innovation (CFI) #41027 to A.F. and D.E.K. Work on variants presented was also  
273 supported by the Sentinelle COVID Quebec network led by the LSPQ in collaboration with Fonds  
274 de Recherche du Québec Santé (FRQS) to A.F. This work was also partially supported by a CIHR  
275 COVID-19 rapid response grant (OV3 170632) and CIHR stream 1 SARS-CoV-2 Variant  
276 Research to M.C. A.F. is the recipient of Canada Research Chair on Retroviral Entry no.  
277 RCHS0235 950-232424. M.C is a Tier II Canada Research Chair in Molecular Virology and  
278 Antiviral Therapeutics. V.M.L. is supported by a FRQS Junior 1 salary award. D.E.K is a FRQS  
279 Merit Research Scholar. G.B.B. is the recipient of an FRQS PhD fellowship. A.L. was supported  
280 by MITACS Accélération postdoctoral fellowships. This work was also supported by NIH grants  
281 AI108545, AI155577, AI149680, and U19AI082630 (to E.J.W.), the University of Pennsylvania  
282 Perelman School of Medicine COVID Fund (to R.R.G. and E.J.W.); the University of Pennsylvania  
283 Perelman School of Medicine 21st Century Scholar Fund (to R.R.G.); and the Paul and Daisy  
284 Soros Fellowship for New Americans (to R.R.G). The funders had no role in study design, data  
285 collection and analysis, decision to publish, or preparation of the manuscript. We declare no  
286 competing interests.

287

288 **AUTHOR CONTRIBUTIONS**

289 A.T. and A.F. conceived the study. A.T., S.Y.G., D.C., G.B.B., L.M., M.B., A.L., C.B.,  
290 G.G.L, Y.B., and A.F. performed, analyzed, and interpreted the experiments. A.T. and R.D.  
291 performed statistical analysis. S.Y.G., M.M.P., R.R.G, G.B.B., A.L., J.O., G.G.L., H.M., G.G., Y.B.,  
292 M.C, A.R.G., E.J.W. and A.F. contributed unique reagents. J.C.W., L.G., C.M., P.A., C.T., D.E.K.,  
293 and V.M.-L. collected and provided clinical samples. G.D.S., J.F., D.E.K., E.J.W., and R.B.  
294 provided scientific input related to VOC and vaccine efficacy. A.T. and A.F. wrote the manuscript  
295 with inputs from others. Every author has read, edited, and approved the final manuscript.

296

297 **DECLARATION OF INTERESTS**

298 A.R.G. is a consultant for Relation Therapeutics. E.J.W. is consulting for or is an advisor for Merck,  
299 Marengo, Janssen, Related Sciences, Synthekine, and Surface Oncology. E.J.W. is a founder of  
300 Surface Oncology, Danger Bio, and Arsenal Biosciences.

301

302 **FIGURE LEGENDS**

303 **Figure 1. RBD-specific IgG and recognition of SARS-CoV-2 Spike variants by vaccine-**  
304 **elicited antibodies in SARS-CoV-2 naïve and previously-infected individuals after the**  
305 **second and the third dose of mRNA vaccine.**

306 **(A)** SARS-CoV-2 vaccine cohort design. The yellow box represents the period under study. **(B)**  
307 Indirect ELISA was performed by incubating plasma samples from naïve and PI donors collected  
308 at V3, V4 and V5 with recombinant SARS-CoV-2 RBD protein. Anti-RBD Ab binding was detected  
309 using HRP-conjugated anti-human IgG. Relative light unit (RLU) values obtained with BSA  
310 (negative control) were subtracted and further normalized to the signal obtained with the anti-RBD  
311 CR3022 mAb present in each plate. **(C-G)** 293T cells were transfected with the indicated full-  
312 length S from different SARS-CoV-2 variants S and stained with the CV3-25 Ab or with plasma  
313 from naïve or PI donors collected at V3, V4 and V5 and analyzed by flow cytometry. The values  
314 represent the median fluorescence intensities (MFI) normalized by CV3-25 Ab binding. **(B-G)**  
315 **(Left panels)** Each curve represents the values obtained with the plasma of one donor at every  
316 time point. Mean of each group is represented by a bold line. **(Right panels)** Plasma samples  
317 were grouped in different time points (V3, V4 and V5). Naïve and PI donors are represented by  
318 red and black points respectively. Undetectable measures are represented as white symbols, and  
319 limits of detection are plotted. Error bars indicate means  $\pm$  SEM. (\*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p <$   
320  $0.001$ ; \*\*\*\*  $p < 0.0001$ ; ns, non-significant). For naïve donors, n (number of individuals) = 20 and  
321 for previously infected donors n=11.

322

323

324

325 **Figure 2. Fc-effector functions and neutralization activities induced by mRNA vaccination**  
326 **in SARS-CoV-2 naïve and previously-infected individuals.**

327 (A) CEM.NKr parental cells were mixed at a 1:1 ratio with CEM.NKr-Spike cells and were used  
328 as target cells. PBMCs from uninfected donors were used as effector cells in a FACS-based  
329 ADCC assay. (B-E) Neutralizing activity was measured by incubating pseudoviruses bearing  
330 SARS-CoV-2 S glycoproteins, with serial dilutions of plasma for 1 h at 37°C before infecting 293T-  
331 ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID<sub>50</sub>) values were determined  
332 using a normalized non-linear regression using GraphPad Prism software. (A-B) (Left panels)  
333 Each curve represents the values obtained with the plasma of one donor at every time point.  
334 Mean of each group is represented by a bold line. (Right panels) Plasma samples were grouped  
335 in different time points (V3, V4 and V5). (C-E) Neutralization activities against several SARS-CoV-  
336 2 variants S were analyzed at the different time points (V3 (C), V4 (D) and V5 (E)). Naïve and PI  
337 donors are represented by red and black points respectively. Undetectable measures are  
338 represented as white symbols, and limits of detection are plotted. Error bars indicate means ±  
339 SEM. (\* p < 0.05; \*\* P < 0.01; \*\*\* p < 0.001; \*\*\*\* p < 0.0001; ns, non-significant). For naïve donors,  
340 n=20 and for previously infected donors n=11.

341  
342 **Figure 3. Mesh correlations of humoral response variables after the second and third dose**  
343 **of the mRNA vaccine.**

344 Edge bundling correlation plots where red and blue edges represent positive and negative  
345 correlations between connected variables, respectively. Only significant correlations (p < 0.05,  
346 Spearman rank test) are displayed. Nodes are color coded based on the grouping of variables  
347 according to the legend. Node size corresponds to the degree of relatedness of correlations. Edge  
348 bundling plots are shown for correlation analyses using six different datasets, i.e., SARS-CoV-2



349 naïve (**A**) or previously infected (**B**) individuals at V3, V4 and V5 respectively. For naïve and  
350 previously infected donors: n=11.

351  
352 **Figure 4. Evolution of the RBD-specific IgG and associated anti-RBD avidity in SARS-CoV-**  
353 **2 naïve and previously-infected individuals vaccinated with a short or a long interval.**

354 (**A**) SARS-CoV-2 vaccine cohorts design. (**B-E**) Indirect ELISA were performed by incubating  
355 plasma samples from naïve (**B, D**) and PI (**C, E**) donors vaccinated with a SI or a LI with  
356 recombinant SARS-CoV-2 RBD protein. The plasmas were collected at different time point from  
357 prior vaccination to after the third dose of mRNA vaccine. Anti-RBD Ab binding was detected  
358 using HRP-conjugated anti-human IgG. (**B-C**) Relative light unit (RLU) values obtained were  
359 normalized to the signal obtained with the anti-RBD CR3022 mAb present in each plate. (**D-E**)  
360 The RBD avidity index corresponded to the value obtained with the stringent (8M urea) ELISA  
361 divided by that obtained without urea. (**B-E**) (**Left panels**) Each curve represents the values  
362 obtained with the plasma of one donor at every time point. (**Right panels**) The bold line represents  
363 the mean of each group. Naïve and PI donors vaccinated with the SI are represented by blue and  
364 yellow lines respectively and naïve and PI donors vaccinated with the LI are represented by red  
365 and black lines respectively. The time of vaccine dose injections is indicated by an associated  
366 colour syringe. Limits of detection are plotted. For naïve donors, n= 45 for the SI and n=30 for the  
367 LI and for previously infected donors n=16 for the SI and n=15 for the LI.

368

369

**Table 1. Characteristics of the vaccinated SARS-CoV-2 cohorts**

		SARS-CoV-2 Naive	SARS-CoV-2 Previously infected
<b>Number</b>		20	11
<b>Age</b>		52 (33-64)	48 (39-65)
<b>Gender</b>	<b>Male (n)</b>	8	8
	<b>Female (n)</b>	12	3
<b>Days between symptom onset and the 1<sup>st</sup> dose<sup>a</sup></b>		N/A	300 (247-321)
<b>Days between the 1<sup>st</sup> and 2<sup>nd</sup> dose<sup>a</sup></b>		111 (76-120)	110 (90-134)
<b>Days between the 2<sup>nd</sup> and 3<sup>rd</sup> dose<sup>a</sup></b>		219 (167-230)	219 (187-235)
<b>Days between the 2<sup>nd</sup> dose and V3<sup>a</sup></b>		21 (17-34)	22 (13-42)
<b>Days between the 2<sup>nd</sup> dose and V4<sup>a</sup></b>		112 (96-156)	113 (90-127)
<b>Days between the 3<sup>rd</sup> dose and V5<sup>a</sup></b>		27 (20-38)	27 (19-37)

370

371 <sup>a</sup> Values displayed are medians, with ranges in parentheses.

372

373 **Table 2. Characteristics of the longitudinal SARS-CoV-2 cohorts vaccinated with a**  
 374 **short or a long interval**

		Short interval		Long interval	
		SARS-CoV-2 Naïve	SARS-CoV-2 Previously infected	SARS-CoV-2 Naïve	SARS-CoV-2 Previously infected
<b>Number</b>		45	16	30	15
<b>Age</b>		35 (22-67)	35 (23-59)	51 (21-64)	47 (29-65)
<b>Gender</b>	<b>Male (n)</b>	21	10	12	10
	<b>Female (n)</b>	24	6	18	5
<b>Days between symptom onset and the 1<sup>st</sup> dose<sup>a</sup></b>		N/A	102 (50-275)	N/A	274 (166-321)
<b>Days between the 1<sup>st</sup> and 2<sup>nd</sup> dose<sup>a</sup></b>		21 (21-35)	21 (21-30)	111 (76-120)	110 (90-134)
<b>Days between the 2<sup>nd</sup> and 3<sup>rd</sup> dose<sup>a</sup></b>		258 (183-342)	276 (244-308)	219 (167-230)	219 (187-235)

375

376 <sup>a</sup> Values displayed are medians, with ranges in parentheses.

377 **STAR METHODS**

378

379 **RESOURCE AVAILABILITY**

380

381 **Lead contact**

382 Further information and requests for resources and reagents should be directed to and will be  
383 fulfilled by the lead contact, Andrés Finzi ([andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca)).

384

385 **Materials availability**

386 All unique reagents generated during this study are available from the Lead contact without  
387 restriction.

388

389 **Data and code availability**

- 390
- All data reported in this paper will be shared by the lead contact  
391 ([andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca)) upon request.
  - This paper does not report original code.
  - Any additional information required to reanalyze the data reported in this paper is available  
394 from the lead contact ([andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca)) upon request.

395

396 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

397

398 **Ethics Statement**

399 All work was conducted in accordance with the Declaration of Helsinki in terms of informed  
400 consent and approval by an appropriate institutional board. Blood samples were obtained from  
401 donors who consented to participate in this research project at CHUM (19.381) and University of

402 Pennsylvania (University of Pennsylvania Institutional Review Board, IRB no. 845061). Plasmas  
403 were isolated by centrifugation and Ficoll gradient, and samples stored at -80°C until use.

404

#### 405 **Human subjects**

406 The study was conducted in 20 SARS-CoV-2 naïve individuals (8 males and 12 females; age  
407 range: 33-64 years) and 11 SARS-CoV-2 previously-infected individuals (8 males and 3 females;  
408 age range: 39-65 years). All this information is summarized in table 1. For the comparison  
409 between the SI and LI, the study was conducted in 45 SARS-CoV-2 naïve individuals (21 males  
410 and 24 females ; age range : 22-67 years) and 16 SARS-CoV-2 previously-infected individuals  
411 (10 males and 6 females ; age range : 23-59 years) for the SI and in 30 SARS-CoV-2 naïve  
412 individuals (12 males and 18 females ; age range : 21-64 years) and 15 SARS-CoV-2 previously-  
413 infected individuals (10 males and 5 females ; age range : 29-65 years) for the LI. All this  
414 information is summarized in table 2. No specific criteria such as number of patients (sample  
415 size), gender, clinical or demographic were used for inclusion, beyond PCR confirmed SARS-  
416 CoV-2 infection in adults and no detection of Abs recognizing the N protein for naïve donors.

417

#### 418 **Plasma and antibodies**

419 Plasma from SARS-CoV-2 naïve and PI donors were collected, heat-inactivated for 1 hour at  
420 56°C and stored at -80°C until ready to use in subsequent experiments. Plasma from uninfected  
421 donors collected before the pandemic were used as negative controls and used to calculate the  
422 seropositivity threshold in our ELISA, ADCC and flow cytometry assays (see below). The RBD-  
423 specific monoclonal antibody CR3022 was used as a positive control in ELISA assays, and the  
424 CV3-25 antibody in flow cytometry assays and were previously described (Anand et al., 2020;  
425 Beaudoin-Bussièrès et al., 2020; Jennewein et al., 2021; Meulen et al., 2006; Prévost et al., 2020).  
426 Horseradish peroxidase (HRP)-conjugated Abs able to detect the Fc region of human IgG

427 (Invitrogen) was used as secondary Abs to detect Ab binding in ELISA experiments. Alexa Fluor-  
428 647-conjugated goat anti-human Abs able to detect all Ig isotypes (anti-human IgM+IgG+IgA;  
429 Jackson ImmunoResearch Laboratories) were used as secondary Ab to detect plasma binding in  
430 flow cytometry experiments.

431  
432 **Cell lines**  
433 293T human embryonic kidney cells (obtained from ATCC) were maintained at 37°C under 5%  
434 CO<sub>2</sub> in Dulbecco's modified Eagle's medium (DMEM) (Wisent) containing 5% fetal bovine serum  
435 (FBS) (VWR) and 100 µg/ml of penicillin-streptomycin (Wisent). CEM.NKr CCR5+ cells (NIH AIDS  
436 reagent program) were maintained at 37°C under 5% CO<sub>2</sub> in Roswell Park Memorial Institute  
437 (RPMI) 1640 medium (Gibco) containing 10% FBS and 100 µg/ml of penicillin-streptomycin.  
438 293T-ACE2 cell line was previously reported (Prévost et al., 2020). CEM.NKr CCR5+ cells stably  
439 expressing the SARS-CoV-2 S glycoproteins were previously reported (Anand et al., 2021;  
440 Beaudoin-Bussièrès et al., 2021).

441  
442 **METHOD DETAILS**

443 **Plasmids**  
444 The plasmids encoding the SARS-CoV-2 S variants (D614G, Delta (B.1.617.2) and Omicron  
445 (B.1.1.529) and the S2 subunit were previously reported (Beaudoin-Bussièrès et al., 2020;  
446 Chatterjee et al., 2021; Gong et al., 2021; Tauzin et al., 2022a). The HCoV-HKU1 S was  
447 purchased from Sino Biological. The plasmids encoding the BA.1.1 and BA.2 S were generated  
448 by overlapping PCR for mutagenesis of a codon-optimized wild-type SARS-CoV-2 S gene  
449 (GeneArt, ThermoFisher) that was synthesized (Biobasic) and cloned in pCAGGS as a template.  
450 All constructs were verified by Sanger sequencing.

451  
452

453 **Protein expression and purification**

454 FreeStyle 293F cells (Invitrogen) were grown in FreeStyle 293F medium (Invitrogen) to a density  
455 of  $1 \times 10^6$  cells/mL at 37°C with 8% CO<sub>2</sub> with regular agitation (150 rpm). Cells were transfected  
456 with a plasmid coding for SARS-CoV-2 S RBD (Beaudoin-Bussi eres et al., 2020) using  
457 ExpiFectamine 293 transfection reagent, as directed by the manufacturer (Invitrogen). One week  
458 later, cells were pelleted and discarded. Supernatants were filtered using a 0.22 µm filter (Thermo  
459 Fisher Scientific). The recombinant RBD proteins were purified by nickel affinity columns, as  
460 directed by the manufacturer (Invitrogen). The RBD preparations were dialyzed against  
461 phosphate-buffered saline (PBS) and stored in aliquots at -80°C until further use. To assess  
462 purity, recombinant proteins were loaded on SDS-PAGE gels and stained with Coomassie Blue.  
463

464 **Enzyme-Linked Immunosorbent Assay (ELISA) and RBD avidity index**

465 The SARS-CoV-2 RBD ELISA assay used was previously described (Beaudoin-Bussi eres et al.,  
466 2020; Pr evost et al., 2020). Briefly, recombinant SARS-CoV-2 S RBD proteins (2.5 µg/ml), or  
467 bovine serum albumin (BSA) (2.5 µg/ml) as a negative control, were prepared in PBS and were  
468 adsorbed to plates (MaxiSorp Nunc) overnight at 4°C. Coated wells were subsequently blocked  
469 with blocking buffer (Tris-buffered saline [TBS] containing 0.1% Tween20 and 2% BSA) for 1h at  
470 room temperature. Wells were then washed four times with washing buffer (Tris-buffered saline  
471 [TBS] containing 0.1% Tween20). CR3022 mAb (50 ng/ml) or a 1/500 dilution of plasma were  
472 prepared in a diluted solution of blocking buffer (0.1 % BSA) and incubated with the RBD-coated  
473 wells for 90 minutes at room temperature. Plates were washed four times with washing buffer  
474 followed by incubation with secondary Abs (diluted in a diluted solution of blocking buffer (0.4%  
475 BSA)) for 1h at room temperature, followed by four washes. To calculate the RBD-avidity index,  
476 we performed in parallel a stringent ELISA, where the plates were washed with a chaotropic  
477 agent, 8M of urea, added of the washing buffer. This assay was previously described (Tauzin et  
478 al., 2022b). HRP enzyme activity was determined after the addition of a 1:1 mix of Western

479 Lightning oxidizing and luminol reagents (Perkin Elmer Life Sciences). Light emission was  
480 measured with a LB942 TriStar luminometer (Berthold Technologies). Signal obtained with BSA  
481 was subtracted for each plasma and was then normalized to the signal obtained with CR3022  
482 present in each plate. The seropositivity threshold was established using the following formula:  
483 mean of pre-pandemic SARS-CoV-2 negative plasma + (3 standard deviation of the mean of pre-  
484 pandemic SARS-CoV-2 negative plasma).

485

### 486 **Cell surface staining and flow cytometry analysis**

487 293T cells were co-transfected with a GFP expressor (pIRES2-GFP, Clontech) in combination  
488 with plasmids encoding the full-length S of SARS-CoV-2 variants (D614G, Delta and Omicron,  
489 BA.1.1 and BA.2), the S2 subunit or the HCoV-HKU1 S. 48h post-transfection, S-expressing cells  
490 were stained with the CV3-25 Ab (Jennewein et al., 2021) or plasma (1/250 dilution). AlexaFluor-  
491 647-conjugated goat anti-human IgM+IgG+IgA Abs (1/800 dilution) were used as secondary Abs.  
492 The percentage of transfected cells (GFP+ cells) was determined by gating the living cell  
493 population based on viability dye staining (Aqua Vivid, Invitrogen). Samples were acquired on a  
494 LSRII cytometer (BD Biosciences) and data analysis was performed using FlowJo v10.7.1 (Tree  
495 Star). The seropositivity threshold was established using the following formula: mean of pre-  
496 pandemic SARS-CoV-2 negative plasma + (3 standard deviation of the mean of pre-pandemic  
497 SARS-CoV-2 negative plasma). The conformational-independent S2-targeting mAb CV3-25 was  
498 used to normalize S expression. CV3-25 was shown to effectively recognize all SARS-CoV-2 S  
499 variants (Chatterjee et al., 2021; Li et al., 2022).

500

### 501 **ADCC assay**

502 This assay was previously described (Anand et al., 2021; Beaudoin-Bussi eres et al., 2021). For  
503 evaluation of anti-SARS-CoV-2 antibody-dependent cellular cytotoxicity (ADCC), parental  
504 CEM.NKr CCR5+ cells were mixed at a 1:1 ratio with CEM.NKr cells stably expressing a GFP-



505 tagged full length SARS-CoV-2 S (CEM.NKr.SARS-CoV-2.Spike cells). These cells were stained  
506 for viability (AquaVivid; Thermo Fisher Scientific, Waltham, MA, USA) and cellular dyes (cell  
507 proliferation dye eFluor670; Thermo Fisher Scientific) to be used as target cells. Overnight rested  
508 PBMCs were stained with another cellular marker (cell proliferation dye eFluor450; Thermo Fisher  
509 Scientific) and used as effector cells. Stained target and effector cells were mixed at a ratio of  
510 1:10 in 96-well V-bottom plates. Plasma (1/500 dilution) or monoclonal antibody CR3022 (1  
511  $\mu\text{g}/\text{mL}$ ) were added to the appropriate wells. The plates were subsequently centrifuged for 1 min  
512 at 300g, and incubated at 37°C, 5% CO<sub>2</sub> for 5 hours before being fixed in a 2% PBS-formaldehyde  
513 solution. ADCC activity was calculated using the formula:  $[(\% \text{ of GFP+ cells in Targets plus}$   
514  $\text{Effectors}) - (\% \text{ of GFP+ cells in Targets plus Effectors plus plasma/antibody})]/(\% \text{ of GFP+ cells in}$   
515  $\text{Targets}) \times 100$  by gating on transduced live target cells. All samples were acquired on an LSRII  
516 cytometer (BD Biosciences) and data analysis was performed using FlowJo v10.7.1 (Tree Star).  
517 The specificity threshold was established using the following formula: mean of pre-pandemic  
518 SARS-CoV-2 negative plasma + (3 standard deviation of the mean of pre-pandemic SARS-CoV-  
519 2 negative plasma).

520

### 521 **Virus neutralization assay**

522 To produce the pseudoviruses, 293T cells were transfected with the lentiviral vector pNL4.3 R-E-  
523 Luc (NIH AIDS Reagent Program) and a plasmid encoding for the indicated S glycoprotein  
524 (D614G, Delta and Omicron, BA.1.1 and BA.2) at a ratio of 10:1. Two days post-transfection, cell  
525 supernatants were harvested and stored at -80°C until use. For the neutralization assay, 293T-  
526 ACE2 target cells were seeded at a density of  $1 \times 10^4$  cells/well in 96-well luminometer-compatible  
527 tissue culture plates (Perkin Elmer) 24h before infection. Pseudoviral particles were incubated  
528 with several plasma dilutions (1/50; 1/250; 1/1250; 1/6250; 1/31250) for 1h at 37°C and were then  
529 added to the target cells followed by incubation for 48h at 37°C. Then, cells were lysed by the  
530 addition of 30  $\mu\text{L}$  of passive lysis buffer (Promega) followed by one freeze-thaw cycle. An LB942

531 TriStar luminometer (Berthold Technologies) was used to measure the luciferase activity of each  
532 well after the addition of 100  $\mu$ L of luciferin buffer (15mM MgSO<sub>4</sub>, 15mM KPO<sub>4</sub> [pH 7.8], 1mM  
533 ATP, and 1mM dithiothreitol) and 50  $\mu$ L of 1mM d-luciferin potassium salt (Prolume). The  
534 neutralization half-maximal inhibitory dilution (ID<sub>50</sub>) represents the plasma dilution to inhibit 50%  
535 of the infection of 293T-ACE2 cells by pseudoviruses.

536

## 537 **QUANTIFICATION AND STATISTICAL ANALYSIS**

### 538 **Statistical analysis**

539 Symbols represent biologically independent samples from SARS-CoV-2 naïve or SARS-CoV-2  
540 PI individuals. Lines connect data from the same donor. Statistics were analyzed using GraphPad  
541 Prism version 8.0.1 (GraphPad, San Diego, CA). Every dataset was tested for statistical normality  
542 and this information was used to apply the appropriate (parametric or nonparametric) statistical  
543 test. Differences in responses for the same patient before and after vaccination were performed  
544 using Wilcoxon tests. Differences in responses between naïve and PI individuals at each time  
545 point (V3, V4 and V5) were measured by Mann-Whitney tests. Differences in responses against  
546 the different S for the same patient were measured by Friedman tests. P values < 0.05 were  
547 considered significant; significance values are indicated as \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001,  
548 \*\*\*\* p < 0.0001. Spearman's R correlation coefficient was applied for correlations. Statistical tests  
549 were two-sided and p < 0.05 was considered significant.

550

### 551 **Software scripts and visualization**

552 Edge bundling graphs were generated in undirected mode in R and RStudio using ggraph, igraph,  
553 tidyverse, and RColorBrewer packages (R Core Team, 2014). Edges are only shown if p < 0.05,  
554 and nodes are sized according to the connecting edges' r values. Nodes are color-coded  
555 according to groups of parameters.

556

## 557 REFERENCES

- 558 Anand, S.P., Prévost, J., Richard, J., Perreault, J., Tremblay, T., Drouin, M., Fournier, M.-J.,  
559 Lewin, A., Bazin, R., and Finzi, A. (2020). High-throughput detection of antibodies targeting the  
560 SARS-CoV-2 Spike in longitudinal convalescent plasma samples (*Microbiology*).
- 561 Anand, S.P., Prévost, J., Nayrac, M., Beaudoin-Bussièrès, G., Benlarbi, M., Gasser, R., Brassard,  
562 N., Laumaea, A., Gong, S.Y., Bourassa, C., et al. (2021). Longitudinal analysis of humoral  
563 immunity against SARS-CoV-2 Spike in convalescent individuals up to eight months post-  
564 symptom onset. *Cell Rep. Med.* 100290. <https://doi.org/10.1016/j.xcrm.2021.100290>.
- 565 Andreano, E., Paciello, I., Piccini, G., Manganaro, N., Pileri, P., Hyseni, I., Leonardi, M., Pantano,  
566 E., Abbiento, V., Benincasa, L., et al. (2021). Hybrid immunity improves B cells and antibodies  
567 against SARS-CoV-2 variants. *Nature* 600, 530–535. [https://doi.org/10.1038/s41586-021-04117-](https://doi.org/10.1038/s41586-021-04117-7)  
568 7.
- 569 Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M.,  
570 Groves, N., O’Connell, A.-M., et al. (2022). Covid-19 Vaccine Effectiveness against the Omicron  
571 (B.1.1.529) Variant. *N. Engl. J. Med.* NEJMoa2119451. <https://doi.org/10.1056/NEJMoa2119451>.
- 572 Beaudoin-Bussièrès, G., Laumaea, A., Anand, S.P., Prévost, J., Gasser, R., Goyette, G.,  
573 Medjahed, H., Perreault, J., Tremblay, T., Lewin, A., et al. (2020). Decline of Humoral Responses  
574 against SARS-CoV-2 Spike in Convalescent Individuals. *MBio* 11.  
575 <https://doi.org/10.1128/mBio.02590-20>.
- 576 Beaudoin-Bussièrès, G., Richard, J., Prévost, J., Goyette, G., and Finzi, A. (2021). A new flow  
577 cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-  
578 expressing cells. *STAR Protoc.* 2, 100851. <https://doi.org/10.1016/j.xpro.2021.100851>.
- 579 Björkman, C., Näslund, K., Stenlund, S., Maley, S.W., Buxton, D., and Ugglå, A. (1999). An IgG  
580 Avidity ELISA to Discriminate between Recent and Chronic *Neospora Caninum* Infection. *J. Vet.*  
581 *Diagn. Invest.* 11, 41–44. <https://doi.org/10.1177/104063879901100106>.
- 582 Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S.Y., Boutin, M., Bourassa, C., Beaudoin-  
583 Bussièrès, G., Bo, Y., Ding, S., Laumaea, A., et al. (2021). SARS-CoV-2 Omicron Spike  
584 recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks  
585 interval between doses.
- 586 Chen, J., Wang, R., Gilby, N.B., and Wei, G.-W. (2022). Omicron Variant (B.1.1.529): Infectivity,  
587 Vaccine Breakthrough, and Antibody Resistance. *J. Chem. Inf. Model.* *acs.jcim.1c01451*.  
588 <https://doi.org/10.1021/acs.jcim.1c01451>.
- 589 Choi, J.Y., and Smith, D.M. (2021). SARS-CoV-2 Variants of Concern. *Yonsei Med. J.* 62, 961–  
590 968. <https://doi.org/10.3349/ymj.2021.62.11.961>.
- 591 Crotty, S. (2021). Hybrid immunity. *Science* 372, 1392–1393.  
592 <https://doi.org/10.1126/science.abj2258>.
- 593 Dhar, M.S., Marwal, R., Vs, R., Ponnusamy, K., Jolly, B., Bhojar, R.C., Sardana, V., Naushin, S.,  
594 Rophina, M., Mellan, T.A., et al. (2021). Genomic characterization and epidemiology of an

- 595 emerging SARS-CoV-2 variant in Delhi, India. *Science* 374, 995–999.  
596 <https://doi.org/10.1126/science.abj9932>.
- 597 Doria-Rose, N.A., Shen, X., Schmidt, S.D., O'Dell, S., McDanal, C., Feng, W., Tong, J., Eaton,  
598 A., Maglinao, M., Tang, H., et al. (2021). Booster of mRNA-1273 Strengthens SARS-CoV-2  
599 Omicron Neutralization. *MedRxiv Prepr. Serv. Health Sci.* 2021.12.15.21267805.  
600 <https://doi.org/10.1101/2021.12.15.21267805>.
- 601 Ferdinands, J.M. (2022). Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against  
602 COVID-19–Associated Emergency Department and Urgent Care Encounters and  
603 Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance —  
604 VISION Network, 10 States, August 2021–January 2022. *MMWR Morb. Mortal. Wkly. Rep.* 71.  
605 <https://doi.org/10.15585/mmwr.mm7107e2>.
- 606 Fialová, L., Petráčková, M., and Kuchař, O. (2017). Comparison of different enzyme-linked  
607 immunosorbent assay methods for avidity determination of antiphospholipid antibodies. *J. Clin.*  
608 *Lab. Anal.* 31, e22121. <https://doi.org/10.1002/jcla.22121>.
- 609 Goel, R.R., Apostolidis, S.A., Painter, M.M., Mathew, D., Pattekar, A., Kuthuru, O., Gouma, S.,  
610 Hicks, P., Meng, W., Rosenfeld, A.M., et al. (2021). Distinct antibody and memory B cell  
611 responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. *Sci.*  
612 *Immunol.* 6. <https://doi.org/10.1126/sciimmunol.abi6950>.
- 613 Gong, S.Y., Chatterjee, D., Richard, J., Prévost, J., Tauzin, A., Gasser, R., Bo, Y., Vézina, D.,  
614 Goyette, G., Gendron-Lepage, G., et al. (2021). Contribution of single mutations to selected  
615 SARS-CoV-2 emerging variants spike antigenicity. *Virology* 563, 134–145.  
616 <https://doi.org/10.1016/j.virol.2021.09.001>.
- 617 Gruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F.,  
618 Sander, L.E., and Klein, F. (2022). mRNA booster immunization elicits potent neutralizing serum  
619 activity against the SARS-CoV-2 Omicron variant. *Nat. Med.* 1–4. [https://doi.org/10.1038/s41591-](https://doi.org/10.1038/s41591-021-01676-0)  
620 [021-01676-0](https://doi.org/10.1038/s41591-021-01676-0).
- 621 Jennewein, M.F., MacCamy, A.J., Akins, N.R., Feng, J., Homad, L.J., Hurlburt, N.K., Seydoux,  
622 E., Wan, Y.-H., Stuart, A.B., Edara, V.V., et al. (2021). Isolation and characterization of cross-  
623 neutralizing coronavirus antibodies from COVID-19+ subjects. *Cell Rep.* 36, 109353.  
624 <https://doi.org/10.1016/j.celrep.2021.109353>.
- 625 Kumar, S., Karuppanan, K., and Subramaniam, G. (2022). Omicron (BA.1) and Sub-Variants  
626 (BA.1, BA.2 and BA.3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative  
627 Sequence and Structural-based Computational Assessment. *bioRxiv* 2022.02.11.480029.  
628 <https://doi.org/10.1101/2022.02.11.480029>.
- 629 Li, W., Chen, Y., Prévost, J., Ullah, I., Lu, M., Gong, S.Y., Tauzin, A., Gasser, R., Vézina, D.,  
630 Anand, S.P., et al. (2022). Structural basis and mode of action for two broadly neutralizing  
631 antibodies against SARS-CoV-2 emerging variants of concern. *Cell Rep.* 38, 110210.  
632 <https://doi.org/10.1016/j.celrep.2021.110210>.
- 633 Meulen, J. ter, Brink, E.N. van den, Poon, L.L.M., Marissen, W.E., Leung, C.S.W., Cox, F.,  
634 Cheung, C.Y., Bakker, A.Q., Bogaards, J.A., Deventer, E. van, et al. (2006). Human Monoclonal

- 635 Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants.  
636 PLOS Med. 3, e237. <https://doi.org/10.1371/journal.pmed.0030237>.
- 637 Miyamoto, S., Arashiro, T., Adachi, Y., Moriyama, S., Kinoshita, H., Kanno, T., Saito, S., Katano,  
638 H., Iida, S., Ainai, A., et al. (2022). Vaccination-infection interval determines cross-neutralization  
639 potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. Med  
640 S2666634022000897. <https://doi.org/10.1016/j.medj.2022.02.006>.
- 641 Nayrac, M., Dubé, M., Sannier, G., Nicolas, A., Marchitto, L., Tastet, O., Tazuin, A., Brassard, N.,  
642 Beaudoin-Bussièrès, G., Vézina, D., et al. (2021). Temporal associations of B and T cell immunity  
643 with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen. BioRxiv Prepr.  
644 Serv. Biol. 2021.12.18.473317. <https://doi.org/10.1101/2021.12.18.473317>.
- 645 Nemet, I., Kliker, L., Lustig, Y., Zuckerman, N., Erster, O., Cohen, C., Kreiss, Y., Alroy-Preis, S.,  
646 Regev-Yochay, G., Mendelson, E., et al. (2022). Third BNT162b2 Vaccination Neutralization of  
647 SARS-CoV-2 Omicron Infection. N. Engl. J. Med. 386, 492–494.  
648 <https://doi.org/10.1056/NEJMc2119358>.
- 649 Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N.,  
650 Faustini, S., Al-Taei, S., Moore, S.C., et al. (2021). Immunogenicity of standard and extended  
651 dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699–5714.e11.  
652 <https://doi.org/10.1016/j.cell.2021.10.011>.
- 653 Prévost, J., Gasser, R., Beaudoin-Bussièrès, G., Richard, J., Duerr, R., Laumaea, A., Anand,  
654 S.P., Goyette, G., Benlarbi, M., Ding, S., et al. (2020). Cross-Sectional Evaluation of Humoral  
655 Responses against SARS-CoV-2 Spike. Cell Rep. Med. 1, 100126.  
656 <https://doi.org/10.1016/j.xcrm.2020.100126>.
- 657 R Core Team (2014). R: A language and environment for statistical computing. R Foundation for  
658 Statistical Computing, Vienna, Austria. URL <http://www.R-project.org/>.
- 659 Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z., Gaebler,  
660 C., Caskey, M., Nussenzweig, M.C., et al. (2022). Plasma Neutralization of the SARS-CoV-2  
661 Omicron Variant. N. Engl. J. Med. 386, 599–601. <https://doi.org/10.1056/NEJMc2119641>.
- 662 Tazuin, A., Nayrac, M., Benlarbi, M., Gong, S.Y., Gasser, R., Beaudoin-Bussièrès, G., Brassard,  
663 N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021). A single dose of the SARS-CoV-2 vaccine  
664 BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. Cell Host Microbe  
665 0. <https://doi.org/10.1016/j.chom.2021.06.001>.
- 666 Tazuin, A., Gong, S.Y., Beaudoin-Bussièrès, G., Vézina, D., Gasser, R., Nault, L., Marchitto, L.,  
667 Benlarbi, M., Chatterjee, D., Nayrac, M., et al. (2022a). Strong humoral immune responses  
668 against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between  
669 doses. Cell Host Microbe 30, 97–109.e5. <https://doi.org/10.1016/j.chom.2021.12.004>.
- 670 Tazuin, A., Gendron-Lepage, G., Nayrac, M., Anand, S.P., Bourassa, C., Medjahed, H., Goyette,  
671 G., Dubé, M., Bazin, R., Kaufmann, D.E., et al. (2022b). Evolution of Anti-RBD IgG Avidity  
672 Following SARS-CoV-2 Infection. Viruses 14, 532. <https://doi.org/10.3390/v14030532>.
- 673 Ullah, I., Prévost, J., Ladinsky, M.S., Stone, H., Lu, M., Anand, S.P., Beaudoin-Bussièrès, G.,  
674 Symmes, K., Benlarbi, M., Ding, S., et al. (2021). Live imaging of SARS-CoV-2 infection in mice

675 reveals that neutralizing antibodies require Fc function for optimal efficacy. *Immunity* S1074-  
676 7613(21)00347-2. <https://doi.org/10.1016/j.immuni.2021.08.015>.

677 Viana, R., Moyo, S., Amoako, D.G., Tegally, H., Scheepers, C., Althaus, C.L., Anyaneji, U.J.,  
678 Bester, P.A., Boni, M.F., Chand, M., et al. (2022). Rapid epidemic expansion of the SARS-CoV-  
679 2 Omicron variant in southern Africa. *Nature* 1–10. <https://doi.org/10.1038/s41586-022-04411-y>.








680 WHO (2022a). Tracking SARS-CoV-2 variants, [https://www.who.int/en/activities/tracking-SARS-  
681 CoV-2-variants/](https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/).

682 WHO (2022b). Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard  
683 With Vaccination Data, <https://covid19.who.int/table>.

684 Young, C., and Brink, R. (2021). The unique biology of germinal center B cells. *Immunity* 54,  
685 1652–1664. <https://doi.org/10.1016/j.immuni.2021.07.015>.

686





**A****B****C****D****E****F****G****Figure 1**



● Naïve

● Previously infected


**A**




**B**




**C**



**D**




**E**








**Figure 2**






**Figure 3**

**A****B****C****D****E****Figure 4**

● Naïve

● Previously infected



**Figure S1 : Recognition of SARS-CoV-2 Spike variants and HCoV-HKU1 S by plasma from naïve and PI donors, Related to Figure 1.**


293T cells were transfected with the S2 subunit (A) or the indicated full-length S from different SARS-CoV-2 variants (C-E) or the HCoV-HKU1 S (B) and stained with the CV3-25 Ab or with plasma from naïve or PI donors collected at V3, V4 and V5 and analyzed by flow cytometry. The values represent the MFI (B) or the MFI normalized by CV3-25 Ab binding (A, C-E). (A-B) Left panel: Each curve represents the values obtained with the plasma of one donor at every time point. Mean of each group is represented by a bold line. Right panel: Plasma samples were grouped in different time points (V3, V4 and V5). (C-E) Binding of plasma collected at V3 (C), V4 (D) and V5 (E). Naïve and PI donors are represented by red and black points respectively, undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means  $\pm$  SEM. (\*  $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ ; \*\*\*\*  $P < 0.0001$ ; ns, non-significant). For naïve donors,  $n=20$  and for previously infected donors  $n=11$ .

● Naïve

● Previously infected


**A**

**Delta**




**B**

**Omicron**




**C**

**BA.1.1**



**D**

**BA.2**




**Figure S2 :Neutralization activities in naïve and previously-infected vaccinated individuals against several SARS-CoV-2 variants, Related to Figure 3.**

(A-D) Neutralizing activity was measured by incubating pseudoviruses bearing SARS-CoV-2 Delta S (A), Omicron S (B), BA.1.1 S (C) or BA.2 S (D) with serial dilutions of plasma for 1 h at 37°C before infecting 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID<sub>50</sub>) values were determined using a normalized non-linear regression using GraphPad Prism software. Naïve and PI donors are represented by red and black points, respectively. Plasma samples were grouped in different time points (V3, V4 and V5). Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means  $\pm$  SEM (\*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001; \*\*\*\*p < 0.0001; ns, non-significant). For naïve donors, n = 20 and for PI donors, n = 11.


— - urea

— + urea



**Figure S3 : Comparison of the detection of RBD specific antibodies between ELISA and stringent ELISA in SARS-CoV-2 naïve and previously infected individuals vaccinated with a short or a long interval, Related to Figure 4.**


(A-D) Indirect ELISA was performed by incubating plasma samples from naïve (A-B) and PI (C-D) vaccinated donors after a short (A, C) or a long (B, D) interval with recombinant SARS-CoV-2 RBD protein. Anti-RBD Ab binding was detected using HRP-conjugated anti-human IgG. Relative light unit (RLU) values obtained were normalized to the signal obtained with the anti-RBD CR3022 mAb present in each plate. For ELISA (black curves), all the wash steps were made with washing buffer and for stringent ELISA (green curves), the wash steps were supplemented with 8M of urea. Each curve represents the normalized RLU obtained with the plasma of one donor at every time point. Mean of each group is represented by a bold line. Limits of detection are plotted. For naïve donors n=46 for the short interval and n=30 for the long interval and for previously infected donors n=16 for the short interval and n=15 for the long interval.



**Figure S4 : Mesh correlations of humoral response parameters after the second and the third dose of mRNA vaccine with the short interval regimen, Related to Figure 4.**

Edge bundling correlation plots where red and blue edges represent positive and negative correlations between connected parameters, respectively. Only significant correlations ( $p < 0.05$ , Spearman rank test) are displayed. Nodes are color coded based on the grouping of parameters according to the legend. Node size corresponds to the degree of relatedness of correlations. Edge bundling plots are shown for correlation analyses using two different datasets; i.e., SARS-CoV-2 naïve individuals vaccinated with the short interval at V3 and V5 respectively.  $n=20$ .





**Figure S5 : Humoral responses in SARS-CoV-2 naïve individuals that received a short dose interval, Related to Figure 4.**

(A) SARS-CoV-2 vaccine cohort design. (B-F) Humoral responses were measured in plasma samples collected after the second (V3) and the third dose (V5) from naïve donors that received a short dose interval. (B) Indirect ELISA was performed by incubating plasma samples with recombinant SARS-CoV-2 RBD protein. Anti-RBD Ab binding was detected using HRP-conjugated anti-human IgG. RLU values obtained were normalized to the signal obtained with the anti-RBD CR3022 mAb present in each plate. (C) Indirect ELISA and stringent ELISA was performed by incubating plasma samples with recombinant SARS-CoV-2 RBD protein. Anti-RBD Ab binding was detected using HRP-conjugated anti-human IgG. RBD avidity index corresponded to the value obtained with the stringent ELISA divided by that obtained with the ELISA. (D) CEM.NKr parental cells were mixed at a 1:1 ratio with CEM.NKr-S cells and were used as target cells. PBMCs from uninfected donors were used as effector cells in a FACS-based ADCC assay. (E) 293T cells were transfected with the indicated full-length S or the S2 subunit and stained with the CV3-25 Ab or with plasma and analyzed by flow cytometry. The values represent the MFI normalized by CV3-25 Ab binding. (F) Neutralizing activity was measured by incubating pseudoviruses bearing SARS-CoV-2 S glycoproteins with serial dilutions of plasma for 1 h at 37°C before infecting 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID<sub>50</sub>) values were determined using a normalized non-linear regression using GraphPad Prism software. Undetectable measures are represented as white symbols, and limits of detection are plotted. Error bars indicate means ± SEM (\*p < 0.05; \*\*p < 0.01; \*\*\*p < 0.001; \*\*\*\*p < 0.0001; ns, non-significant). n = 20.